Fig. 2.

a Illustration of the experimental protocols. Arrow indicates time of intravenous administration of the inhibitors of RISK [PD-98059 (PD), LY-294002 (LY)] or SAFE pathways [AG490 (AG)]. b PD and LY abolished cardioprotection established by immediate IPost (IPost10″), but had no effect on cardioprotection conferred by early IPost (IPost10′). AG had no effect on the immediate or early IPost cardioprotection. Infarct sizes are presented as percentages of the areas at risk. Individual data and mean ± SD are shown. **P < 0.01; *P < 0.05; n.s.—not significant